Open AccessIntravitreal bevacizumab (avastin) for circumscribed choroidal hemangioma
Author(s) -
Shramana Mandal,
Prashant Naithani,
Pradeep Venkatesh,
Satpal Garg
Publication year - 2011
Publication title -
indian journal of ophthalmology/indian journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 51
eISSN - 1998-3689
pISSN - 0301-4738
DOI - 10.4103/0301-4738.81051
Subject(s) - medicine , bevacizumab , verteporfin , serous fluid , ophthalmology , retinal , photodynamic therapy , choroid , fluorescein angiography , aflibercept , laser coagulation , choroidal neovascularization , visual acuity , retina , surgery , pathology , chemotherapy , chemistry , physics , organic chemistry , optics
Circumscribed choroidal hemangiomas are rare ophthalmic entities that cause diminution in vision due to accumulation of subretinal and/or intraretinal fluid in the macular area. Various treatment options ranging from conventional laser to photodynamic therapy have been employed to destroy the tumor and reduce the exudation; however, either the inability to penetrate through the exudative fluid or the collateral retinal damage induced by these treatment modalities make them unsuitable for lesions within the macula. We evaluated the role of intravitreal bevacizumab, a pan-vascular endothelial growth factor (VEGF) inhibitor, in reducing the sub- and intraretinal fluid in three patients with circumscribed choroidal hemangiomas. All the patients had complete resolution of the serous retinal detachment that was maintained till at least 12 months after the first injection. Intravitreal bevacizumab may be used in combination with thermal laser or photodynamic therapy in treating circumscribed choroidal hemangiomas with subretinal fluid.